Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
CRBP
CRBP
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
CRBP News
Corbus Secures FDA Alignment on CRB-701 Pathway
Apr 07 2026
Newsfilter
Corbus Aligns with FDA on CRB-701 Registration Pathway
Apr 07 2026
NASDAQ.COM
FDA Approves Corbus' Registrational Study Design
Apr 07 2026
Newsfilter
Corbus Pharmaceuticals Reports Q4 2025 Financial Results
Mar 09 2026
seekingalpha
Corbus Pharmaceuticals Reports 2025 Financial Results and Clinical Updates
Mar 09 2026
Newsfilter
Corbus Pharmaceuticals: 46% Stake Held by Retail Investors Influencing Management
Dec 27 2025
Yahoo Finance
Biotech Surge Post-Market: Inspira, MediciNova, and DiaMedica Therapeutics Among Top Performers
Dec 19 2025
NASDAQ.COM
Corbus Shares Drop After Initial Results for Oral Obesity Treatment CRB-913
Dec 11 2025
SeekingAlpha
Corbus Pharmaceuticals' CRB-913 Achieves 2.9% Weight Loss in Obese Patients
Dec 11 2025
Newsfilter
Corbus Announces Encouraging Phase 1a Results for CRB-913 in Obesity, Shares Rise - Update
Dec 11 2025
NASDAQ.COM
Corbus Pharma Set to Announce Phase 1a Results for CRB-913 in Obesity Today
Dec 11 2025
NASDAQ.COM
Biotech Stocks Rise in After-Hours Trading Driven by Data Expectations and Momentum Buying
Dec 11 2025
NASDAQ.COM
Corbus Pharmaceuticals to Release Phase 1a Results for CRB-913 on December 11, 2025
Dec 10 2025
Globenewswire
Corbus Pharmaceuticals to Release CRB-913 Phase 1a Data on December 11, 2025
Dec 10 2025
Newsfilter
RBC Capital Keeps Outperform Rating for Corbus Pharmaceuticals, Reduces Price Target to $53
Nov 13 2025
Benzinga
Roku, SPS Commerce, Newell Brands, and Other Major Stocks Decline in Friday's Pre-Market Trading
Oct 31 2025
Benzinga
Show More News
